Maria P. Hernandez-Fuentes

Maria P. Hernandez-Fuentes

Auto-generated profile, based on publicly available information

Maria P. Hernandez-Fuentes

MRC Centre for Transplantation, King's College London, Great Maze Pond, London SE1 9RT, UK; King's Health Partners, Guy's Hospital, London SE1 9RT, UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KNKenneth A. Newell
Kenneth A. Newell
AAAdam Asare
Adam Asare
AKAllan D. Kirk
Allan D. Kirk
TGTrang D. Gisler
Trang D. Gisler
KBKasia Bourcier
Kasia Bourcier
VSVicki L. Seyfert-Margolis
Vicki L. Seyfert-Margolis
Establishing long-term allograft acceptance without the requirement for continuous immunosuppression, a condition known as allograft tolerance, is a highly desirable therapeutic goal in solid organ transplantation. Determining which recipients would benefit from withdrawal or minimization of immunosuppression would be greatly facilitated by biomarkers predictive of tolerance. In this study, we identified the largest reported cohort to our knowledge of tolerant renal transplant recipients, as defined by stable graft function and receiving no immunosuppression for more than 1 year, and compared their gene expression profiles and peripheral blood lymphocyte subsets with those of subjects with stable graft function who are receiving immunosuppressive drugs as well as healthy controls. In addition to being associated with clinical and phenotypic parameters, renal allograft tolerance was strongly associated with a B cell signature using several assays. Tolerant subjects showed increased expression of multiple B cell differentiation genes, and a set of just 3 of these genes distinguished tolerant from nontolerant recipients in a unique test set of samples. This B cell signature was associated with upregulation of CD20 mRNA in urine sediment cells and elevated numbers of peripheral blood naive and transitional B cells in tolerant participants compared with those receiving immunosuppression. These results point to a critical role for B cells in regulating alloimmunity and provide a candidate set of genes for wider-scale screening of renal transplant recipients.

1 May 2020 in The Lancet
Verified
Journal Article
Closed access
BSBirgit Sawitzki
Birgit Sawitzki
PHPaul N Harden
Paul N Harden
PRPetra Reinke
Petra Reinke
AMAurélie Moreau
Aurélie Moreau
JHJames A Hutchinson
James A Hutchinson
EGEdward K Geissler
Edward K Geissler

1 June 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PSPervinder Sagoo
Pervinder Sagoo
EPEsperanza Perucha
Esperanza Perucha
BSBirgit Sawitzki
Birgit Sawitzki
STStefan Tomiuk
Stefan Tomiuk
DSDavid A. Stephens
David A. Stephens
RLRobert I. Lechler
Robert I. Lechler
Identifying transplant recipients in whom immunological tolerance is established or is developing would allow an individually tailored approach to their posttransplantation management. In this study, we aimed to develop reliable and reproducible in vitro assays capable of detecting tolerance in renal transplant recipients. Several biomarkers and bioassays were screened on a training set that included 11 operationally tolerant renal transplant recipients, recipient groups following different immunosuppressive regimes, recipients undergoing chronic rejection, and healthy controls. Highly predictive assays were repeated on an independent test set that included 24 tolerant renal transplant recipients. Tolerant patients displayed an expansion of peripheral blood B and NK lymphocytes, fewer activated CD4+ T cells, a lack of donor-specific antibodies, donor-specific hyporesponsiveness of CD4+ T cells, and a high ratio of forkhead box P3 to α-1,2-mannosidase gene expression. Microarray analysis further revealed in tolerant recipients a bias toward differential expression of B cell–related genes and their associated molecular pathways. By combining these indices of tolerance as a cross-platform biomarker signature, we were able to identify tolerant recipients in both the training set and the test set. This study provides an immunological profile of the tolerant state that, with further validation, should inform and shape drug-weaning protocols in renal transplant recipients.

18 January 2007 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MMM. Martínez-Llordella
M. Martínez-Llordella
IPI Puig-Pey
I Puig-Pey
GOG. Orlando
G. Orlando
MRM. Ramoni
M. Ramoni
GTG. Tisone
G. Tisone
ASA. Sánchez-Fueyo
A. Sánchez-Fueyo
Immunosuppressive drugs can be completely withdrawn in up to 20% of liver transplant recipients, commonly referred to as ‘operationally’ tolerant. Immune characterization of these patients, however, has not been performed in detail, and we lack tests capable of identifying tolerant patients among recipients receiving maintenance immunosuppression. In the current study we have analyzed a variety of biological traits in peripheral blood of operationally tolerant liver recipients in an attempt to define a multiparameter ‘fingerprint’ of tolerance. Thus, we have performed peripheral blood gene expression profiling and extensive blood cell immunophenotyping on 16 operationally tolerant liver recipients, 16 recipients requiring on-going immunosuppressive therapy, and 10 healthy individuals. Microarray profiling identified a gene expression signature that could discriminate tolerant recipients from immunosuppression-dependent patients with high accuracy. This signature included genes encoding for γδ T-cell and NK receptors, and for proteins involved in cell proliferation arrest. In addition, tolerant recipients exhibited significantly greater numbers of circulating potentially regulatory T-cell subsets (CD4+CD25+ T-cells and Vδ1+ T cells) than either non-tolerant patients or healthy individuals. Our data provide novel mechanistic insight on liver allograft operational tolerance, and constitute a first step in the search for a non-invasive diagnostic signature capable of predicting tolerance before undergoing drug weaning.

11 April 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JCJohn C Chambers
John C Chambers
WZWeihua Zhang
Weihua Zhang
GLGraham MIchael Lord
Graham MIchael Lord
PHPim van der Harst
Pim van der Harst
DLDebbie A Lawlor
Debbie A Lawlor
JKJaspal S Kooner
Jaspal S Kooner

24 February 2015 in Gut
Verified
Journal Article
Open access
PDF file
JCJames B Canavan
James B Canavan
CSCristiano Scottà
Cristiano Scottà
AVAnna Vossenkämper
Anna Vossenkämper
RGRimma Goldberg
Rimma Goldberg
MEMatthew J Elder
Matthew J Elder
GLGraham MIchael Lord
Graham MIchael Lord
Background and aim Thymus-derived regulatory T cells (Tregs) mediate dominant peripheral tolerance and treat experimental colitis. Tregs can be expanded from patient blood and were safely used in recent phase 1 studies in graft versus host disease and type 1 diabetes. Treg cell therapy is also conceptually attractive for Crohn's disease (CD). However, barriers exist to this approach. The stability of Tregs expanded from Crohn's blood is unknown. The potential for adoptively transferred Tregs to express interleukin-17 and exacerbate Crohn's lesions is of concern. Mucosal T cells are resistant to Treg-mediated suppression in active CD. The capacity for expanded Tregs to home to gut and lymphoid tissue is unknown. Methods To define the optimum population for Treg cell therapy in CD, CD4+CD25+CD127loCD45RA+ and CD4+CD25+CD127loCD45RA− Treg subsets were isolated from patients’ blood and expanded in vitro using a workflow that can be readily transferred to a good manufacturing practice background. Results Tregs can be expanded from the blood of patients with CD to potential target dose within 22–24 days. Expanded CD45RA+ Tregs have an epigenetically stable FOXP3 locus and do not convert to a Th17 phenotype in vitro, in contrast to CD45RA− Tregs. CD45RA+ Tregs highly express α4β7 integrin, CD62L and CC motif receptor 7 (CCR7). CD45RA+ Tregs also home to human small bowel in a C.B-17 severe combined immune deficiency (SCID) xenotransplant model. Importantly, in vitro expansion enhances the suppressive ability of CD45RA+ Tregs. These cells also suppress activation of lamina propria and mesenteric lymph node lymphocytes isolated from inflamed Crohn's mucosa. Conclusions CD4+CD25+CD127loCD45RA+ Tregs may be the most appropriate population from which to expand Tregs for autologous Treg therapy for CD, paving the way for future clinical trials.